The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
about
ZNF423 and ZNF521: EBF1 Antagonists of Potential Relevance in B-Lymphoid MalignanciesHoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid LeukemiaALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens.Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancersDeciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenanceGenomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors reveals RET as a potential therapeutic target.Dysregulation of haematopoietic stem cell regulatory programs in acute myeloid leukaemia.Functional interdependence of BRD4 and DOT1L in MLL leukemia.Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions.MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.Coordination of Myeloid Differentiation with Reduced Cell Cycle Progression by PU.1 Induction of MicroRNAs Targeting Cell Cycle Regulators and Lipid Anabolism.Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells.Pharmacological inhibition of the transcription factor PU.1 in leukemia.BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells.The cancer-associated U2AF35 470A>G (Q157R) mutation creates an in-frame alternative 5' splice site that impacts splicing regulation in Q157R patients.De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations.Dysregulated transcriptional networks in and -rearranged T-ALLTAP: a targeted clinical genomics pipeline for detecting transcript variants using RNA-seq data
P2860
Q26770729-80EF7D0D-BA85-4C64-81A2-CD2E54C4D44DQ33558976-3856D241-85A9-40C6-A064-0DECE5F94DBAQ33687080-C72E6612-EA02-4CCD-80D4-64CA13F191BAQ36283942-8087BECF-7F98-4EDD-9E50-E3F7EA28C816Q36984373-6AF1DF9E-F928-46DC-A088-44A45072A444Q37215879-45DFF6E8-CEE9-4DF2-85B0-F87E35DB1C9DQ37278032-A16627DA-4269-421A-9B31-4FFDEDEDC9EFQ37306997-505E5928-C342-4D68-B23D-26142BD869BEQ37559783-070BC423-DB6C-4732-AF90-B7A0B0EB3A8BQ37633585-F0AAB2A2-8E8A-4392-953B-3FE15BE37FBDQ38429500-792A4646-6541-4B4E-87ED-DFC44839BDA9Q38703904-888F283B-9C5E-40C1-8D9B-83A4E26F8696Q38813967-B84015D2-FD6A-4932-BCE7-DF0AE18B54AFQ38860767-CD435FE6-2FD4-4E1A-9AD0-F20AA0BC6872Q38892311-D7C9507D-C19D-4304-9EC0-CFC4DA89FF0FQ39249858-234D64DE-ED9D-444E-80AD-513A2BAB6A97Q39253931-DB2DD953-EBD6-4881-839D-D098CB19D744Q39688289-D787BF09-4C9F-4D2F-A286-ADB25E774CEAQ42263242-28F2221E-FCA7-4208-8E82-2353893E4F75Q42314704-0E3E5ACB-4695-470A-913E-6D9360D25166Q42987231-FDE02A7C-F851-4C57-B203-CFB5DA117AC7Q43539014-8F5DCEB3-12C8-4A46-AF21-DB03022F6B24Q46873766-6F0B9933-E8A1-498A-A793-0DF2BD74D160Q47155915-BCD7FBC4-DC05-4C9B-B138-5EFFF2060C24Q47820600-E50B411E-0E70-4AF1-8A84-7365B31C3D09Q52714487-CA0C86CC-4511-4C64-BA44-7DC599C4AA37Q52885541-65CB1C0A-4382-4A5B-AFC8-AD16B4A685B3Q56518873-90632551-7439-42EC-88EB-6EECCD871AC5Q58755295-8C4E001F-6D8B-418E-832B-160E6CC8833C
P2860
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The transcriptomic landscape a ...... anged acute myeloid leukemias.
@en
The transcriptomic landscape a ...... anged acute myeloid leukemias.
@nl
type
label
The transcriptomic landscape a ...... anged acute myeloid leukemias.
@en
The transcriptomic landscape a ...... anged acute myeloid leukemias.
@nl
prefLabel
The transcriptomic landscape a ...... anged acute myeloid leukemias.
@en
The transcriptomic landscape a ...... anged acute myeloid leukemias.
@nl
P2093
P2860
P50
P356
P1433
P1476
The transcriptomic landscape a ...... anged acute myeloid leukemias.
@en
P2093
Anne Marinier
Brian Wilhelm
Frédéric Barabé
Guy Sauvageau
Irène Baccelli
Jana Krosl
Josée Hébert
Sylvain Meloche
Vincent-Philippe Lavallée
P2860
P2888
P304
P356
10.1038/NG.3371
P407
P577
2015-08-03T00:00:00Z